The US FDA has issued a warning to Curaleaf, which it says is selling CBD products with improper claims to treat diseases like cancer, withdrawal from opioids, pain, and anxiety
Written by CannIntelligence || 25th July 2019 || News analysis | Regulation and legislation | North America United States